Murid Herpesvirus

Murid herpesvirus (MuHV), commonly known as Murine Gammaherpesvirus 68 (MHV-68), is a naturally occurring pathogen of wild rodents that has become one of the most valuable experimental models for studying gammaherpesvirus biology. As a member of the Herpesviridae family, subfamily Gammaherpesvirinae, MuHV shares significant genetic and biological features with two major human pathogens: Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV). Because EBV and KSHV are strictly species-specific and cannot be studied directly in small animal models, MuHV provides a tractable, high-throughput system to investigate virus-host interactions, latency establishment, immune evasion, and oncogenic mechanisms. Its ability to establish lifelong latent infection in laboratory mice makes it an indispensable tool for understanding gammaherpesvirus pathogenesis and for developing antiviral and vaccine strategies.

Figure 1. Virion Architecture and Genomic Organization of Murid Herpesvirus.

Life Cycle and Pathogenesis

MuHV infection in laboratory mice recapitulates many features of EBV and KSHV infection in humans. Following intranasal inoculation—the natural route of infection—the virus replicates productively in respiratory epithelial cells, leading to acute pneumonitis. From this initial site, the virus disseminates to draining lymph nodes and the spleen, where it infects B lymphocytes and establishes latency. During latency, the viral genome persists as a circular episome in the nucleus of infected cells, with only a limited set of viral genes expressed. These latency-associated genes promote B-cell proliferation and survival, allowing the virus to maintain a lifelong reservoir. Periodic reactivation can occur, leading to lytic replication and shedding, which facilitates transmission to new hosts. The severity of disease depends on the host immune status. In immunocompetent mice, acute infection is typically self-limiting, and latency is well-controlled. However, in immunocompromised animals (e.g., those deficient in T cells, interferon signaling, or perforin), MuHV can cause severe lymphoproliferative disease, lymphomas, and vasculitis—paralleling the EBV-associated lymphoproliferative disorders seen in transplant recipients or AIDS patients.

Key Molecular Targets and Pathological Pathways

The pathogenesis of MuHV is orchestrated by a set of viral proteins that manipulate host cell signaling, immune surveillance, and cell survival pathways. These proteins represent key molecular targets for therapeutic intervention and are the focus of extensive research.

Applications

Applications in Antiviral and Vaccine Development

The MuHV model has been instrumental in evaluating:

• Antiviral compounds: Inhibitors of viral DNA polymerase (e.g., cidofovir), protein kinase (e.g., maribavir), and lytic reactivation (e.g., ORF50 inhibitors) have been tested in vivo.
• Vaccine strategies: Live-attenuated, subunit, and viral-vector vaccines have been assessed for their ability to prevent acute infection, reduce latency, and block transmission.
• Immunotherapies: Adoptive T-cell transfer and checkpoint blockade approaches have been validated in MuHV-infected immunocompromised mice.

Conclusions

Murid herpesvirus (MHV-68) is far more than a pathogen of rodents; it is a sophisticated experimental platform that has illuminated fundamental principles of gammaherpesvirus biology. Through the study of its key molecular targets—from the lytic switch protein ORF50 and latency factor ORF73 to immune modulators like M3 and anti-apoptotic ORF11—researchers have gained deep insights into viral persistence, immune evasion, and oncogenesis. As the global burden of EBV- and KSHV-associated diseases remains substantial, the MuHV model will continue to play a pivotal role in advancing our understanding and developing new therapeutic and preventive strategies.

Murid Herpesvirus Antibody

Murid Herpesvirus Antigens